AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
4.2.2026 15:45:00 CET | ACCESS Newswire | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments
MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.
The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.
AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.
Best in KLAS® - Enterprise Imaging (United States)
Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.
XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive year
Enterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year.
"Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."
Commenting on the awards, Adam Gale, CEO of KLAS Research, said:
"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."
Monique Rasband, Global Vice President of Imaging at KLAS Research, added:
"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."
The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.
AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.
KLAS references
Best in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services Report
Enterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services Report
About AGFA HealthCare
At AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.
This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.
AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
About KLAS Research
KLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.
Best in KLAS® is a registered trademark of KLAS Research.
Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.com
SOURCE: Agfa HealthCare
View the original press release on ACCESS Newswire
Agfa HealthCare
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner3.2.2026 11:30:00 CET | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors. Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-sui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom